Abstract
Currently approved drug eluting stents (DES) consist of a metallic scaffold and an elutable drug dispersed in a polymer matrix that conformally surrounds the struts. These primarily biostable polymers bind the drug to the stent and modulate the elution of the drug into the arterial tissue. This chapter summarizes the key requirements for polymers used in the DES, including physical properties, stability, compatibility with drugs, biocompatibility with vascular tissue and control of drug release. An in-depth analysis of polymer structure, coating design, drug-polymer morphology and drug elution profile is provided for the four currently marketed DES: CYPHER® Sirolimus- eluting Coronary Stent, Taxus® / Taxus Liberte®, XIENCE V™ / Promus® and Endeavor®. A new generation of DES is being developed using bioabsorbable polymers which degrade over time and leave behind a bare metal stent. This includes the RES TECHNOLOGY™ platform employed in the NEVO™ Sirolimus-eluting Coronary Stent which is explored with respect to polymer composition, degradation profile and drug release kinetics.
Keywords: Polymers, Eluting Stents, drug-polymer morphology, local drug delivery, biostable, bioabsorbable, drug delivery, stent, restenosis, coronary angioplasty, neointimal hyperplasia, bare metal stent, sterilization, cobalt chromium alloy, poly(butyl methacrylate), PBMA, ethylene oxide, esters, amides, anhydrides, reendothelialization, Cypher, Xience V, Promus, Endeavor, Parylene C, Sirolimus, isobutylene, styrene, oxidation, SIBS phase, PVDF-HFP, methacrylated phosphorylcholine, lauryl methacrylate, hydroxypropyl methacrylate, trimethylsilyl methacrylate, polyorthoesters, DL-lactide, glycolide, ethylene glycol
Current Pharmaceutical Design
Title: Polymers for Drug Eluting Stents
Volume: 16 Issue: 36
Author(s): Ted Parker, Vipul Dave and Robert Falotico
Affiliation:
Keywords: Polymers, Eluting Stents, drug-polymer morphology, local drug delivery, biostable, bioabsorbable, drug delivery, stent, restenosis, coronary angioplasty, neointimal hyperplasia, bare metal stent, sterilization, cobalt chromium alloy, poly(butyl methacrylate), PBMA, ethylene oxide, esters, amides, anhydrides, reendothelialization, Cypher, Xience V, Promus, Endeavor, Parylene C, Sirolimus, isobutylene, styrene, oxidation, SIBS phase, PVDF-HFP, methacrylated phosphorylcholine, lauryl methacrylate, hydroxypropyl methacrylate, trimethylsilyl methacrylate, polyorthoesters, DL-lactide, glycolide, ethylene glycol
Abstract: Currently approved drug eluting stents (DES) consist of a metallic scaffold and an elutable drug dispersed in a polymer matrix that conformally surrounds the struts. These primarily biostable polymers bind the drug to the stent and modulate the elution of the drug into the arterial tissue. This chapter summarizes the key requirements for polymers used in the DES, including physical properties, stability, compatibility with drugs, biocompatibility with vascular tissue and control of drug release. An in-depth analysis of polymer structure, coating design, drug-polymer morphology and drug elution profile is provided for the four currently marketed DES: CYPHER® Sirolimus- eluting Coronary Stent, Taxus® / Taxus Liberte®, XIENCE V™ / Promus® and Endeavor®. A new generation of DES is being developed using bioabsorbable polymers which degrade over time and leave behind a bare metal stent. This includes the RES TECHNOLOGY™ platform employed in the NEVO™ Sirolimus-eluting Coronary Stent which is explored with respect to polymer composition, degradation profile and drug release kinetics.
Export Options
About this article
Cite this article as:
Parker Ted, Dave Vipul and Falotico Robert, Polymers for Drug Eluting Stents, Current Pharmaceutical Design 2010; 16 (36) . https://dx.doi.org/10.2174/138161210794454897
DOI https://dx.doi.org/10.2174/138161210794454897 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Alsevirone-NF Reduces Serum Testosterone and Inhibits Prostate Cancer Xenograft Growth in Balb/c Nude Mice
Clinical Cancer Drugs Epigenetics in Alzheimers Disease: a Focus on DNA Modifications
Current Pharmaceutical Design An Unbiased Predictive Model to Detect DNA Methylation Propensity of CpG Islands in the Human Genome
Current Bioinformatics Targeting Ion Channels for New Strategies in Cancer Diagnosis and Therapy
Current Clinical Pharmacology Lipoxygenase Inhibitors for Cancer Prevention: Promises and Risks
Current Pharmaceutical Design Bone Morphogenetic Proteins and its Receptors; Therapeutic Targets in Cancer Progression and Bone Metastasis?
Current Pharmaceutical Design Targeting Malignancies with Disulfiram (Antabuse): Multidrug Resistance, Angiogenesis, and Proteasome
Current Cancer Drug Targets Imatinib Reduces the Vasculogenic Potential of Plastic Tumor Cells
Current Angiogenesis (Discontinued) Host Innate Immune Responses to Microbial Pathogens
Current Vascular Pharmacology Diffusion-Weighted Magnetic Resonance Imaging in Pelvic Cancer
Current Medical Imaging The Role of Cytochrome P450 in Cytotoxic Bioactivation: Future Therapeutic Directions
Current Cancer Drug Targets New Approach to Cancer Therapy: The Application of Signal Transduction to Anti-Cancer Drug
Current Medicinal Chemistry - Anti-Cancer Agents Quantum Dots and Their Clinical Applications
Nanoscience & Nanotechnology-Asia Treating Benign Prostatic Hyperplasia with Botulinum Neurotoxin
Current Medicinal Chemistry KCa3.1 Channels and Glioblastoma: In Vitro Studies
Current Neuropharmacology Molecular Modeling Studies of Estrogen Receptor Modulators
Current Computer-Aided Drug Design Withdrawal Notice: Drug Repurposing for Prospective Anti-Cancer Agents Along with the Clinical Status of the Repurposed Drug
Anti-Cancer Agents in Medicinal Chemistry Transglutaminase-Mediated Activation of Nuclear Transcription Factor-κB in Cancer Cells: A New Therapeutic Opportunity
Current Cancer Drug Targets Progress Towards Clinically Useful Aldosterone Synthase Inhibitors
Current Topics in Medicinal Chemistry Subject Index to Volume 10
Current Pharmaceutical Design